UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000047844
Receipt number R000054546
Scientific Title Utility of dual energy CT for metastatic bone tumor detection
Date of disclosure of the study information 2022/05/25
Last modified on 2023/07/02 11:02:00

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Utility of dual energy CT for metastatic bone tumor detection

Acronym

Value of DECT for bone metastasis detection

Scientific Title

Utility of dual energy CT for metastatic bone tumor detection

Scientific Title:Acronym

Value of DECT for bone metastasis detection

Region

Japan


Condition

Condition

metastatic bone tumor

Classification by specialty

Radiology Adult

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

Computed tomography(CT) is well recognized tool for screening
metastatic lesion in cancer patients. However, when it comes to
metastatic bone tumors(MBT),CT has the lowest sensitivity for detection compared with MRI, PET, and bone scintigraphy. Virtual non-calcium image(VNCa) which can be made by scanning with dual-energy CT has potential to improve detectability of bone marrow abnormalities.
Recently, VNCa showed better detectability rate of multiple myeloma on
VNCa than on standard CT image. Hence, in this study we attempt to see
if the detectability of MBT on CT improve with creating VNCa. MRl is
going to be used as a gold standard image.

Basic objectives2

Others

Basic objectives -Others

evaluate the difference of CT number between MBT and normal bone marrow on VNCa

Trial characteristics_1

Confirmatory

Trial characteristics_2

Explanatory

Developmental phase

Not applicable


Assessment

Primary outcomes

See if there is a significant difference in diagnostic performance for MBT detection between conventional CT (CCT) image only and CCT with VNCa by visual analysis. MRI is used as a reference.

Key secondary outcomes

Measure and see the difference in CT number between normal marrow and MBT on VNCa.


Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

Patients with MBT in the spine

Key exclusion criteria

too poor performance status to
participate this study
patients who needs emergent surgery
patients who have contraindication for MRI

Target sample size

16


Research contact person

Name of lead principal investigator

1st name Takeshi
Middle name
Last name Fukuda

Organization

The Jikei University School of Medicine

Division name

Department of Radiology

Zip code

105-8471

Address

3-25-8, Nishi-shimbashi, Minato-ku, Tokyo

TEL

0334331111

Email

takeshifukuda@jikei.ac.jp


Public contact

Name of contact person

1st name Takeshi
Middle name
Last name Fukuda

Organization

The Jikei University School of Medicine

Division name

Department of Radiology

Zip code

105-8471

Address

3-25-8, Nishi-shimbashi, Minato-ku, Tokyo

TEL

0334331111

Homepage URL


Email

takeshifukuda@jikei.ac.jp


Sponsor or person

Institute

The Jikei University Schoolo of Medicine

Institute

Department

Personal name



Funding Source

Organization

GE healthcare pharma

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization

Japan


Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

The Jikei University School of Medicine

Address

3-25-8, Nishi-shimbashi, Minato-ku, Tokyo

Tel

0336331111

Email

rinri@jikei.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2022 Year 05 Month 25 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Enrolling by invitation

Date of protocol fixation

2022 Year 03 Month 14 Day

Date of IRB

2022 Year 03 Month 14 Day

Anticipated trial start date

2022 Year 06 Month 01 Day

Last follow-up date

2024 Year 12 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

compare the diagnostic performance for MBT between CCT and CCT with VNCa


Management information

Registered date

2022 Year 05 Month 24 Day

Last modified on

2023 Year 07 Month 02 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000054546


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name